To better assess the tumor-suppressing potential specifically due to the inhibition of FGFR4, we evaluated the effect of small molecular FGFR4 inhibitors on ovarian cancer cell lines in vitro and in vivo. This evidence concerns the gene FGFR4 and ovarian carcinoma.